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Th1/Th2 cross-regulation and the discovery of IL-10
In the late 1980s, Tim Mosmann and colleagues isolated functionally distinct 
T helper (Th)-1 and Th2 clones, and provided evidence that these two subsets 
were mutually inhibitory. Knowledge of the inhibition led to the discovery 
that Th2 cells make IL-10 to suppress Th1 cells.
In 1971, C.R. Parish showed that a 
B cell (humoral) response depended on 
the interaction between T and B cells. 
In the absence of such an interaction, 
T cells mediated delayed type hyper-
sensitivity (DTH; a form of cell-mediated 
immunity) instead (1). Both of these 
functions were soon attributed to CD4+ 
T cells, which by then were thought to 
be a heterogeneous population (2).
Building a model
But direct proof of multiple CD4+ T cell 
subsets was a long time in coming. Until 
the mid-1980s, the field lacked two 
critical techniques: the ability to generate 
and maintain long-term T cell clones in 
vitro; and assays to detect and measure 
T cell–secreted cytokines.
By 1986, Mosmann, then at DNAX 
Research Institute (Palo Alto, CA), had 
the necessary techniques. Working 
with Robert Coffman, his team sur-
veyed 50 clones for the expression of 
7 cytokines, and separated them into 
Th1 clones secreting IL-2 and IFNγ, 
and Th2 clones producing a growth 
factor (later identified as IL-4) for B cells 
and mast cells (3).
This clonal dichotomy backed up 
Parish’s findings from the previous 
decade. The Th1 cytokines promoted 
DTH, whereas the Th2 cytokines 
enhanced immunoglobulin (Ig) synthesis 
and class switching (4). Furthermore, 
the Th1-derived cytokine IFNγ inhib-
ited the proliferation of Th2 but not 
Th1 clones (5).
“Here was a mechanism to explain 
how an immune reaction got polarized 
into a Th1 or Th2 response,” says 
Mosmann. The clones secreted cyto-
kines that were both autocrine growth 
factors and suppressors of the prolifer  ation 
and activity of the opposite cell type. 
A breakdown in this Th1/Th2 balance 
might explain why some immune reac-
tions had fatal outcomes.
Finding a “friendly” cytokine
Mosmann’s group set about finding the 
reverse link—a Th2-derived cytokine 
that would inhibit IFNγ synthesis by 
Th1 clones. Success came at stunning 
speed. Before research technician David 
Fiorentino had finished his first week in 
Mosmann’s lab, he found that all of the 
activated Th2 clones secreted a factor 
that blocked IFNγ synthesis. They 
called it “cytokine synthesis inhibitory 
factor” (CSIF).
The mystery factor perfectly fit the 
profile of a cross-regulator: it did not 
inhibit Th2 cytokine synthesis; it was 
not made by Th1 cells; and it inhibited 
production of Th1 cytokines other 
than IFNγ, such as IL-2 and TNF. 
The novel activity was not removed by 
depletion of known cytokines such as 
IL-3, IL-4, and IL-5. Mosmann hoped 
the team had found a new suppressing 
cytokine; “our only worry,” he recalls, 
“was that this factor might turn out to 
be TGFβ,” a well-known suppressive 
cytokine. But an anti-TGFβ antibody 
failed to reduce CSIF activity. Mosmann’s 
group published their results in The 
Journal of Experimental Medicine in 1989 
(6), just as they began their attempts to 
purify CSIF.
Protein instability drove the group 
from biochemistry to cloning. Kevin 
Moore and Paulo Vieira (then at DNAX) 
made cDNA libraries from Th2 clones 
supplied by Mosmann’s group and used 
expression assays to identify what was 
rechristened as IL-10 (7).
This project “was one of the few 
times when things worked exactly accord-
ing to our hypothesis,” says Mosmann. 
From identifying CSIF to the cloning 
of IL-10, each step worked perfectly. 
“IL-10 was really a very friendly cyto-
kine,” he says.
Colleagues at DNAX later found that 
IL-10 acted directly on macrophages (8), 
lowering their IL-12 production and 
thus Th1 differentiation (9). IL-10’s 
known functions later expanded: it is 
produced by both innate and adaptive 
immune cell types and limits not only 
Th1 but, in some cases, Th2 responses 
(10). IL-10 curbs inflammation in vivo 
primarily by inhibiting cytokine produc-
tion by or activation of innate immune 
cells (9). In its absence, inflammation can 
escalate to tissue-damaging levels.
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